MedTrace Logo

A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

NCT00140855 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-10-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.

Conditions

  • Synovial Sarcoma

Interventions

BIOLOGICAL

ipilimumab

Sponsors & Collaborators

  • Medarex

    collaborator INDUSTRY

  • Ludwig Institute for Cancer Research

    lead OTHER

Principal Investigators

  • Robert G Maki, MD PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-08
Primary Completion
2007-04-18
Completion
2007-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00140855 on ClinicalTrials.gov